The promise of stem cell research is being realized by biotechnology companies bringing the discoveries of great scientists out of the academic world, into therapeutic development, and to the market where they can be delivered to patients in need. Athersys Incorporated (Athersys), based in Cleveland, Ohio, is one of these biotechnology companies. Considered a clinical-stage biotechnology company, Athersys is developing therapies created using adult stem cells isolated from bone marrow and other tissue sources. They refer to these stem cells as multipotent adult progenitor cells (MAPC), which can be expanded on a large scale following isolation from a donor. Athersys’s current programs are based in part on the proprietary product under the registered trademark name MultiStem but also involve the use of their RAGE (Random ...

  • Loading...
locked icon

Sign in to access this content

Get a 30 day FREE TRIAL

  • Watch videos from a variety of sources bringing classroom topics to life
  • Read modern, diverse business cases
  • Explore hundreds of books and reference titles